Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol 2021;39(Suppl):Abstract LBA5.

• PubMed
Choueiri TK, Tomczak P, Park SH, Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol 2021;39(Suppl):Abstract LBA5.)| false
• Search Google Scholar
• Export Citation

Berg SA, McGregor BA. Adjuvant immunotherapy in resected renal cell carcinoma: déjà vu or progress? ASCO Daily News. Published February 9, 2023. Available at: https://dailynews.ascopubs.org/do/adjuvant-immunotherapy-resected-renal-cell-carcinoma-deja-vu-progress

• PubMed
Berg SA, McGregor BA. Adjuvant immunotherapy in resected renal cell carcinoma: déjà vu or progress? ASCO Daily News. Published February 9, 2023. Available at: https://dailynews.ascopubs.org/do/adjuvant-immunotherapy-resected-renal-cell-carcinoma-deja-vu-progress)| false
• Search Google Scholar
• Export Citation

US Food and Drug Administration. FDA approved pembrolizumab for adjuvant treatment of renal cell carcinoma. Accessed April 8, 2024. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma

• PubMed
US Food and Drug Administration. FDA approved pembrolizumab for adjuvant treatment of renal cell carcinoma. Accessed April 8, 2024. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma)| false
• Search Google Scholar
• Export Citation

Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 3.2024. Accessed April 8, 2024. To view the most recent version, visit https://www.nccn.org

• PubMed
Motzer RJ, Jonasch E, Agarwal N, NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 3.2024. Accessed April 8, 2024. To view the most recent version, visit https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591–597.

• PubMed
Choueiri TK, Halabi S, Sanford BL, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591–597.)| false
• Search Google Scholar
• Export Citation

Tannir NM, Escudier B, McDermott DF, et al. Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol 2024;42(Suppl):Abstract 363.

• PubMed
Tannir NM, Escudier B, McDermott DF, Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol 2024;42(Suppl):Abstract 363.)| false
• Search Google Scholar
• Export Citation

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116–1127.

• PubMed
Rini BI, Plimack ER, Stus V, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116–1127.)| false
• Search Google Scholar
• Export Citation

Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829–841.

• PubMed
Choueiri TK, Powles T, Burotto M, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829–841.)| false
• Search Google Scholar
• Export Citation

Motzer RJ, Porta C, Alekseev B, et al. Health-related quality-of-life analysis from the phase 3 CLEAR trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol 2021;39(Suppl):Abstract 4502.

• PubMed
Motzer RJ, Porta C, Alekseev B, Health-related quality-of-life analysis from the phase 3 CLEAR trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol 2021;39(Suppl):Abstract 4502.)| false
• Search Google Scholar
• Export Citation

Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med 2023;388:1767–1778.

• PubMed
Choueiri TK, Powles T, Albiges L, Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med 2023;388:1767–1778.)| false
• Search Google Scholar
• Export Citation

Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 2023;402:185–195.

• PubMed
Pal SK, Albiges L, Tomczak P, Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 2023;402:185–195.)| false
• Search Google Scholar
• Export Citation

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–927.

• PubMed
Choueiri TK, Escudier B, Powles T, Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–927.)| false
• Search Google Scholar
• Export Citation

Albiges L, Schmidinger M, Taguieva-Pioger N, et al. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol 2022;18:915–926.

• PubMed
Albiges L, Schmidinger M, Taguieva-Pioger N, CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol 2022;18:915–926.)| false
• Search Google Scholar
• Export Citation

Procopio G, Claps M, Pircher C, et al. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03). Tumori 2023;109:129–137.

• PubMed
Procopio G, Claps M, Pircher C, A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03). Tumori 2023;109:129–137.)| false
• Search Google Scholar
• Export Citation

Albiges L, Rini BI, Peltola K, et al. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study. Ann Oncol 2023;34(Suppl 2):S1329–1330.

• PubMed
Albiges L, Rini BI, Peltola K, LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study. Ann Oncol 2023;34(Suppl 2):S1329–1330.)| false
• Search Google Scholar
• Export Citation

Choueiri TK, Bauer T, Merchan JR, et al. LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma. Ann Oncol 2023;34(Suppl 2):S1328–1329.

• PubMed
Choueiri TK, Bauer T, Merchan JR, LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma. Ann Oncol 2023;34(Suppl 2):S1328–1329.)| false
• Search Google Scholar
• Export Citation

Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24:881–891.

• PubMed
Albiges L, Gurney H, Atduev V, Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24:881–891.)| false
• Search Google Scholar
• Export Citation